Razoxane and Radiotherapy for Lung Cancer
Author Information
Author(s): C.E. Newman, R. Cox, C.H.J. Ford, J.R. Johnson, D.R. Jones, M. Wheaton
Primary Institution: Memorial University of Newfoundland
Hypothesis
Does razoxane improve survival when combined with radiotherapy for inoperable lung cancer?
Conclusion
Razoxane combined with radiotherapy resulted in poorer survival compared to radiotherapy alone.
Supporting Evidence
- Median survival time in the razoxane group was 80 days and in the placebo group it was 175 days.
- The sequential design showed that the razoxane group was experiencing poorer survival.
- Razoxane was significantly inferior to placebo with a hazard ratio of 1.76.
Takeaway
This study found that a drug called razoxane made patients with lung cancer live shorter lives when used with radiation therapy.
Methodology
A double-blind, placebo-controlled trial comparing survival between patients receiving razoxane and those receiving placebo alongside radiotherapy.
Potential Biases
Potential bias due to lack of direct assessment of patient compliance.
Limitations
The trial was terminated early due to observed inferiority of razoxane, limiting the validity of standard analyses.
Participant Demographics
Patients with untreated non-small cell or unknown histology lung cancer, no evidence of metastatic disease.
Statistical Information
P-Value
0.05
Confidence Interval
(1.16, 2.83)
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website